Effectiveness of aprepitant in post-acute COVID19 syndrome.
Rocio Reinoso-ArijaCecilia Lopez RamirezJosé Antonio Jimenez-RuizJosé Luis López-CamposPublished in: Clinical case reports (2021)
This is the first case of a patient taking aprepitant for a post-acute COVID-19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.